Epigenetics: rethinking of drug research and development

Future Medicinal ChemistryAhead of Print EditorialEpigenetics: rethinking of drug research and developmentKenneth LundstromKenneth Lundstrom*Author for correspondence: E-mail Address: lundstromkenneth@gmail.comPan Therapeutics, 1095 Lutry, SwitzerlandSearch for more papers by this authorPublished Online:19 Nov 2019https://doi.org/10.4155/fmc-2019-0174AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biotechnologydrug developmentdrug discoveryepigeneticsinfectious disease therapeuticsmolecular biologyneurological therapeuticsoncological therapeuticsReferences1. Lundstrom K. Epigenetics, nutrition, disease and drug development. Curr. Drug Discov. Technol. doi: 10.2174/1570163815666180419154954 [Epub ahead of print] (2018).Crossref, Medline, Google Scholar2. Su LJ, Mahabir S, Ellison GL, McGuinn LA, Reid BC. Epigenetic contributions to the relationship between cancer and dietary intake of nutrients, bioactive food components and environmental toxicants. Front Genet. 2,91 (2012).Crossref, Medline, Google Scholar3. Lundstrom K. MicroRNA in disease and gene therapy. Curr. Drug Discov. Technol. 8(2), 76–86 (2011).Crossref, Medline, CAS, Google Scholar4. Park H, Chung H, Lee J et al. Decitabine as a first-line treatment for older adults newly diagnosed with acute myeloid leukemia. Yonsei Med. J. 58(1), 35–42 (2017).Crossref, Medline, CAS, Google Scholar5. Kaminskas E, Farrell AT, Wang Y-C et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza™) for injectable suspension. Oncologist 10(3), 176–182 (2005).Crossref, Medline, CAS, Google Scholar6. Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247–1252 (2007).Crossref, Medline, CAS, Google Scholar7. Poole RM. Belinostat: first global approval. Drugs 74(13), 1543–1554 (2014).Crossref, Medline, CAS, Google Scholar8. Oki Y, Buglio D, Fanale M et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin. Cancer Res. 19(24), 6882–6890 (2013).Crossref, Medline, CAS, Google Scholar9. Adams D, Gonzalez-Duarte A, O’Riordan WD et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379(1), 11–21 (2018).Crossref, Medline, CAS, Google Scholar10. Cazaly E, Saad K, Wang W et al. Making sense of the epigenome using data integration approaches. Front. Pharmacol. 10, 126 (2019).Crossref, Medline, CAS, Google Scholar11. Padalino G, Ferla S, Brancale A et al. Combining bioinformatics, chemoinformatics, functional genomics and whole organism approaches for identifying epigenetic drug targets in Schistosoma mansoni. Int. J. Parasitol. Drugs Resist. 8(3), 559–570 (2018).Crossref, Medline, Google Scholar12. Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat. Med. 25(3), 403–418 (2019).Crossref, Medline, CAS, Google Scholar13. Kantarjian HM, Roboz GJ, Kropf PL et al. Guadcitabine (SGI-110) in treatment-naïve patients with the acute myeloid leukemia: Phase II results from multicentre, randomised, Phase I/II trial. Lancet Oncol. 18(10), 1317–1326 (2017).Crossref, Medline, CAS, Google Scholar14. Woods D, Sodré AL, Villagra A et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. CanceImmunol. Res. 3(12), 1375–1385 (2015).CAS, Google Scholar15. Dzobo K. Epigenomics-guided drug development: recent advances in solving the cancer treatment “jigsaw puzzle”. OMICS 23(2), 70–85 (2019).Crossref, Medline, CAS, Google Scholar16. Marimani M, Ahmad A, Duse A. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection. Tuberculosis (Edinb.) 113, 200–214 (2018).Crossref, Medline, CAS, Google Scholar17. Lascano S, Lopez M, Arimondo PB. Natural products and chemical biology tools: alternatives to target epigenetic mechanisms in cancers. Chem. Rec. 18(12), 1854–1876 (2018).Crossref, Medline, CAS, Google Scholar18. Ribich S, Harvey D, Copeland RA. Drug discovery and chemical biology of cancer epigenetics. Cell Chem. Biol. 24(9), 1120–1147 (2017).Crossref, Medline, CAS, Google Scholar19. Manchia M, Fanos V. Targeting aggression in severe mental illness: the predictive role of genetic, epigenetic, and metabolic markers. Prog. Neuropsychopharmacol. Biol. Psychiatry 77, 32–41 (2017).Crossref, Medline, Google Scholar20. Lockwood LE, Su S, Youssef NA. The role of epigenetics in depression and suicide: a platform for gene-environment interactions. Psychiatry Res. 228(3), 235–242 (2015).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print Follow us on social media for the latest updates Metrics Downloaded 69 times History Received 29 May 2019 Accepted 4 October 2019 Published online 19 November 2019 Information© 2019 Newlands PressKeywordsbiotechnologydrug developmentdrug discoveryepigeneticsinfectious disease therapeuticsmolecular biologyneurological therapeuticsoncological therapeuticsFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download